Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs.
Administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to dogs produces clinical, pathological and neurological features in dog resembling human Parkinson's disease. Using this animal model, we studied the changes in diurnal rhythms of urine volume, creatinine in urine, and vasopressin, aldosterone and renin activity in plasma. Before MPTP treatment, urine volume showed a peak between 17.00 and 1.00 and plasma vasopressin concentration also showed a clear circadian rhythm with a peak at 13.00 and a minimum level at 5.00. Two weeks after MPTP treatment (2.5 mg/kg i.v.), the rhythm of urine volume disappeared and that of vasopressin became less clear. Plasma renin activity increased 2 and 4 weeks after MPTP treatment. The increase was, however, not enough to change the concentration of plasma aldosterone. We examined the effect of L-3,4-dihydroxyphenylalanine (levodopa), on the circadian pattern of urine volume and vasopressin attenuated by MPTP. Levodopa (4 mg/kg/day) was administered orally every day from the first week after MPTP treatment. The circadian rhythms of urine volume and vasopressin reappeared within one week after the start of levodopa administration.
Hineno
T
T
Department of Neuropsychiatry, Ehime University School of Medicine, Japan.
Mizobuchi
M
M
Hiratani
K
K
Inami
Y
Y
Kakimoto
Y
Y
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000450:Aldosterone / Q000097:blood; D000818:Animals; D002940:Circadian Rhythm / Q000502:physiology*; D004195:Disease Models, Animal; D004285:Dogs; D008297:Male; D010302:Parkinson Disease, Secondary / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology* / Q000652:urine; D012083:Renin / Q000097:blood; D014667:Vasopressins / Q000097:blood
D014667:Vasopressins; D000450:Aldosterone; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D012083:Renin